Efficacy of Changing to DUOTRAV® From Prior Therapy

Inclusion Criteria: * Clinical diagnosis of ocular hypertension, open-angle or pigment dispersion glaucoma in at least one eye. * Stable IOP-lowering regimen of bimatoprost 0.03%/timolol 0.5% therapy (either administered concomitantly or in a fixed combination) within 4 weeks prior to the screening visit. * IOP considered to be safe (in the opinion of the investigator), in both eyes, to assure clinical stability of vision and the optic nerve throughout the study period. * IOP between 19 to 35 mmHg (at any time of the day) in at least one eye (which would be designated as the study eye). * Willing to discontinue the use of all other ocular hypotensive medication(s) prior to receiving the study medication for the entire course of the study. * Able to follow instructions and willing and able to attend all study visits. * Best corrected visual acuity of 6/60 (20/200 Snellen, 1.0 LogMAR) or better in each eye. * Sign informed consent. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Known medical history of allergy, hypersensitivity or poor tolerance to any component of DuoTrav® that is deemed clinically significant in the opinion of the Principal Investigator. * Corneal dystrophies in either eye. * Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment. * Bronchial asthma or a history of bronchial asthma, bronchial hyper reactivity, or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker. * History of severe allergic rhinitis. * A condition, which in the opinion of the Principal Investigator, would interfere with optimal participation in the study, or which would present a special risk to the subject. * Participation in any other investigational study within 30 days prior to the Screening Visit. * Other protocol-defined exclusion criteria may apply.